Core Viewpoint - Hims&Hers Health experienced a significant stock price fluctuation, with a 16% increase followed by a more than 10% decline, resulting in a total drop of 15% over two days, erasing previous gains [1] Company Developments - The company has launched an affordable treatment plan for individuals in perimenopause and menopause, expanding its business into the hormone replacement therapy sector [1] - Hims&Hers anticipates that this new specialized service will help its "Hers" division achieve an annual revenue exceeding $1 billion next year [1]